The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.

The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.

Inventions relate to medicine, pharmacology, biotechnology, molecular biology, genetic engineering and can be used for analgesia. A plasmid DNA for transient expression in mammalian cells is proposed and represented by DNA backbone containing prokaryotic and eukaryotic elements, as well as a fragment providing enhanced capture of plasmid DNA by cells and a polynucleotide encoding beta-endorphin modified for increasing the affinity for receptors and codon-optimized for expression in mammalian cells. There are also proposed a producer of such plasmid DNA on the basis of a bacterial cell and an analgesic agent for application in mammals, in particular, humans, on its basis. The technical result of the use of the developed plasmid DNA and analgesic based on it is to increase the controllability of the synthesis of beta-endorphin exactly, in increasing the efficiency of plasmid DNA from which beta-endorphin is synthesized, and reducing its amount to achieve analgesia, in increasing the duration of analgesia and in expanding the spectrum of analgesic drugs.

There are described methods for the prophylaxis or treatment of pain in a mammal wherein the method comprising administering to the mammal an effective amount of a pain inhibitor comprising a pain inhibiting peptide having an amino acid sequence of more than 6 contiguous arginine residues, or a physiologically acceptable salt of the peptide. The pain inhibitor can be administered in combination with at least one analgesic and/or at least one anti-inflammatory drug. Pharmaceutical compositions comprising the pain inhibitor together with at least one analgesic and/or at least one anti-inflammatory drug are also provided. The pain may, for example, be selected from one or more of neuropathic pain, inflammatory pain, idiopathic pain and nociceptive pain.

There are described methods for the prophylaxis or treatment of pain in a mammal wherein the method comprising administering to the mammal an effective amount of a pain inhibitor comprising a pain inhibiting peptide having an amino acid sequence of more than 6 contiguous arginine residues, or a physiologically acceptable salt of the peptide. The pain inhibitor can be administered in combination with at least one analgesic and/or at least one anti-inflammatory drug. Pharmaceutical compositions comprising the pain inhibitor together with at least one analgesic and/or at least one anti-inflammatory drug are also provided. The pain may, for example, be selected from one or more of neuropathic pain, inflammatory pain, idiopathic pain and nociceptive pain.

The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.

The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.

The present invention relates to a method for determining whether a patient is likely to benefit from treatment with a therapeutic formulation, the method comprising the steps of: (a) determining the concentration of corticotropin releasing hormone (CRH) in a sample from a patient prior to administration of the therapeutic formulation; (b) determining the concentration of CRH in a sample from a patient subsequent to administration of the therapeutic formulation; and (c) comparing the concentration of CRH pre-administration with the concentration of CRH subsequent to administration; wherein an increase in patient CRH concentration subsequent to administration indicates that the patient is likely to benefit from treatment with the therapeutic formulation and wherein no increase or a decrease in patient CRH concentration subsequent to administration indicates that the patient is unlikely to benefit from treatment with the therapeutic formulation. The patient may have multiple sclerosis or systemic sclerosis. The therapeutic formulation may be derived from an ungulate such as a goat and may contain CRH, CRH-binding protein, pro-opiomelanocortin (POMC) and alpha-2 macroglobulin. Also provided are methods of treating a patient with a disorder such as multiple sclerosis or systemic sclerosis.

Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.

The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.